Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.49 |
| ▸ | WNT1 | P04628 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580709 | 0.80 | TDP1 (0.51) | HDAC3HDAC2HDAC1SMN1; SMN2 | |
| SCHEMBL4579334 | 0.79 | HPGDS (0.40) | HDAC3HDAC2HDAC10HDAC6HDAC1 | |
| SCHEMBL4579810 | 0.77 | HDAC3 (0.79) | HDAC3HDAC2HDAC10HDAC6KCNH2 | |
| SCHEMBL4579682 | 0.76 | HDAC2 (1.00) | HDAC3HDAC2KCNH2HDAC1 | |
| SCHEMBL20163063 | 0.76 | HDAC3 (0.59) | HDAC3HDAC2HDAC10HDAC6KCNH2 | |
| SCHEMBL20163145 | 0.75 | HDAC2 (0.51) | HDAC3HDAC2HDAC10WNT1GSK3B | |
| SCHEMBL1066552 | 0.74 | ABL1 (0.52) | HDAC3HDAC2HDAC1 | |
| SCHEMBL4579383 | 0.74 | HDAC2 (0.44) | HDAC3HDAC2HDAC10HDAC6KCNH2 | |
| SCHEMBL1067900 | 0.73 | CHRM4 (0.55) | HDAC3HDAC2HDAC10HDAC6KCNH2 | |
| SCHEMBL4578392 | 0.73 | MCHR1 (0.73) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC3 3/4885HDAC2 5/4885HDAC10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.